8-K: Poseida Therapeutics Announces Promising Phase 1 Data for Allogeneic CAR-T Therapies at AACR 2024

Poseida Therapeutics presented new data at the AACR 2024 meeting, highlighting the potential of their allogeneic CAR-T therapies, P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors, including the need for optimized lymphodepletion regimens.

Summary

• Poseida Therapeutics presented updated Phase 1 data for their allogeneic CAR-T therapies at the American Association for Cancer Research (AACR) Annual Meeting 2024.
• The data includes a subgroup analysis of the P-BCMA-ALLO1 study in relapsed/refractory multiple myeloma patients who had progressed after prior BCMA-targeted therapies.
• Three out of five (60%) patients in this subgroup achieved clinical responses, specifically a very good partial response (VGPR), with P-BCMA-ALLO1.
• The P-BCMA-ALLO1 treatment was well-tolerated with no dose-limiting toxicities, graft vs. host disease, or severe cytokine release syndrome (CRS) or immune effector cell neurotoxicity syndrome (ICANS).
• A separate analysis highlighted the need for higher doses of cyclophosphamide in the lymphodepletion regimen for solid tumor patients compared to multiple myeloma patients to achieve adequate CAR-T cell expansion.
• This finding is being applied to the P-MUC1C-ALLO1 trial for solid tumors to optimize treatment efficacy.
• The company plans to share more comprehensive data sets for both the BCMA and MUC1-C programs in the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical data for Poseida's CAR-T therapies, particularly in a challenging patient population. The identification of the need for optimized lymphodepletion regimens is also a positive step towards improving treatment efficacy. The company's strategic collaboration with Roche further enhances the positive outlook.

Positives

• P-BCMA-ALLO1 demonstrated clinical activity in heavily pretreated multiple myeloma patients, including those who had progressed on prior BCMA-targeted therapies.
• The allogeneic CAR-T therapy is available off-the-shelf, eliminating the need for lengthy manufacturing times associated with autologous CAR-T therapies.
• The study showed no cases of dose-limiting toxicities or graft-versus-host disease.
• The company's proprietary genetic editing platforms and manufacturing capabilities are supporting the development of these therapies.
• The company has a global strategic collaboration with Roche to advance cell therapies for hematological malignancies.

Negatives

• The data presented for P-BCMA-ALLO1 is from a small subgroup of five patients, which may not be fully representative of the broader patient population.
• The need for higher doses of cyclophosphamide in solid tumor patients may present additional challenges in terms of tolerability and side effects.
• The study is still in Phase 1, and further clinical trials are needed to confirm the efficacy and safety of these therapies.

Risks

• The company relies on third parties for various aspects of its business, which could impact timelines and outcomes.
• There are inherent risks and uncertainties associated with the development and regulatory approval of novel biopharmaceutical products.
• Interim data from clinical trials may change as more patient data becomes available.
• Subgroup data may differ from future results of the same study once additional data has been received.
• The company's ability to retain key scientific or management personnel is crucial for continued success.

Future Outlook

Poseida plans to share more comprehensive datasets on both their BCMA and MUC1-C programs in the second half of 2024.

Management Comments

• Bhagirathbhai Dholaria, M.D., stated that new treatment options are urgently needed for patients with relapsed multiple myeloma, and he is encouraged by the Phase 1 subgroup results.
• Syed Rizvi, M.D., mentioned that the new findings provide additional evidence that their investigational, off-the-shelf allogeneic CAR-T therapy could be an appropriate treatment for a broader range of patients with multiple myeloma.
• Syed Rizvi, M.D., also stated that they continue to explore the optimal lymphodepletion regimen for CAR-T in solid tumors.

Industry Context

The announcement is relevant to the broader industry trend of developing novel immunotherapies, particularly CAR-T cell therapies, for cancer treatment. The focus on allogeneic CAR-T therapies addresses the limitations of autologous CAR-T therapies, such as manufacturing challenges and patient-specific requirements. The research into optimizing lymphodepletion regimens is also a key area of focus in the field.

Comparison to Industry Standards

• Autologous CAR-T therapies like Abecma and Carvykti have shown high response rates in multiple myeloma, but they are limited by manufacturing challenges and the need for patient-specific cell collection.
• Poseida's allogeneic approach aims to overcome these limitations by using off-the-shelf T-cells from healthy donors.
• The 60% response rate in heavily pretreated patients with P-BCMA-ALLO1 is promising, especially considering that these patients had progressed on prior BCMA-targeted therapies.
• The need for higher cyclophosphamide doses in solid tumor patients is consistent with the challenges of achieving effective lymphodepletion in this patient population, which is different from the hematological malignancy patient population.
• Companies like Allogene Therapeutics and CRISPR Therapeutics are also developing allogeneic CAR-T therapies, making this a competitive space.

Stakeholder Impact

• Shareholders may view the positive clinical data as a positive sign for the company's future prospects.
• Patients with relapsed/refractory multiple myeloma and solid tumors may benefit from these novel therapies.
• Employees of Poseida Therapeutics may be motivated by the progress of the company's research and development programs.
• The collaboration with Roche may provide additional resources and support for the company's growth.

Next Steps

• Further enrollment in the Phase 1 study is ongoing.
• The company will conduct extensive biomarker and correlative analysis to understand drivers of response and mechanisms of resistance.
• Poseida plans to share more comprehensive datasets on both their BCMA and MUC1-C programs in the second half of 2024.
• Continued evaluation of lymphodepletion regimens is needed as part of developing investigational allogeneic CAR-T in solid tumors.

Key Dates

Keywords

CAR-T therapy, allogeneic, multiple myeloma, solid tumors, P-BCMA-ALLO1, P-MUC1C-ALLO1, lymphodepletion, AACR 2024, cancer, immunotherapy, clinical trial